Global Xerophthalmia Treatment

Xerophthalmia Treatment Comprehensive Study by Type (Cyclosporin, Oral Corticosteroids, Artificial Tears, Punctal Plugs, Omega Supplement), Application (Hospital Pharmacies, Eye Health Clinics), Age group (Preschool-Age Children, Adolescents, Pregnant Women), Ocular Signs (Night Blindness (XN), Conjunctival Xerosis (X1A), Bitot Spots (X1B), Corneal Xerosis (X2), Corneal Ulceration/Keratomalacia, Corneal Ulceration/Keratomalacia, Corneal Scar (XS), Xerophthalmic Fundus (XF)) Players and Region - Global Market Outlook to 2024

Xerophthalmia Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Xerophthalmia Treatment Market Scope
Xerophthalmia is an eye disease caused by vitamin A deficiency. Xerophthalmia is developed into night blindness and other serious damage to the cornea. This damage takes the form of white spots on eyes and ulcers on corneas. Night blindness is an early symptom. When the human body doesn’t produce vitamin A on its own. Xerophthalmia is less seen in the United States, the United Kingdom, and other developed countries. It mostly finds in developing countries where humans have limited access to animal products.

The market study is being classified by Type (Cyclosporin, Oral Corticosteroids, Artificial Tears, Punctal Plugs and Omega Supplement), by Application (Hospital Pharmacies and Eye Health Clinics) and major geographies with country level break-up.

The market is fragmented by key vendors who are focusing on production technologies, improving efficiency and shelf life. Growth opportunities can be captured by tracking the ongoing process improvement and financial flexibility to invest in optimal strategies

Novartis AG (Switzerland), Otsuka Pharmaceutical Co., Ltd. (Japan), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Santen Pharmaceutical Co Ltd (Japan), Sun Pharmaceutical Industries Ltd (India), Medifit Biologicals (India), Sentiss (India), Lupin Limited (India) and FDC Limited (India) are some of the key players profiled in the study.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Xerophthalmia Treatment market by Type, Application and Region.

On the basis of geography, the market of Xerophthalmia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Age group, the sub-segment i.e. Preschool-Age Children will boost the Xerophthalmia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Ocular Signs, the sub-segment i.e. Night Blindness (XN) will boost the Xerophthalmia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In Oct 2018, MeiraGTx Holdings announced an agreement with the National Institute of Dental of Health & Human Services. Through this agreement, MeiraGTx receives worldwide rights to adeno-associated virus vector-mediated gene delivery of aquaporin with xerophthalmia patients.


Market Trend
  • Increasing No. Of Children Are At Higher Risk of Vitamin A Deficiency and Xerophthalmia

Market Drivers
  • Increasing Night Blindness Patients
  • Increase Number of Disease Such As Cornea and Conjunctiva, Such As Conjunctival Xerosis, Bitot Spots, Corneal Xerosis and Keratomalacia

Opportunities
  • Strong Encouragement from the Government

Restraints
  • High Cost of Drugs and Treatment


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Xerophthalmia drugs Suppliers and Distributors, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Cyclosporin
  • Oral Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Omega Supplement
By Application
  • Hospital Pharmacies
  • Eye Health Clinics
By Age group
  • Preschool-Age Children
  • Adolescents
  • Pregnant Women

By Ocular Signs
  • Night Blindness (XN)
  • Conjunctival Xerosis (X1A)
  • Bitot Spots (X1B)
  • Corneal Xerosis (X2)
  • Corneal Ulceration/Keratomalacia
  • Corneal Ulceration/Keratomalacia
  • Corneal Scar (XS)
  • Xerophthalmic Fundus (XF)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Night Blindness Patients
      • 3.2.2. Increase Number of Disease Such As Cornea and Conjunctiva, Such As Conjunctival Xerosis, Bitot Spots, Corneal Xerosis and Keratomalacia
    • 3.3. Market Trends
      • 3.3.1. Increasing No. Of Children Are At Higher Risk of Vitamin A Deficiency and Xerophthalmia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Xerophthalmia Treatment, by Type, Application, Age group, Ocular Signs and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Xerophthalmia Treatment (Value)
      • 5.2.1. Global Xerophthalmia Treatment by: Type (Value)
        • 5.2.1.1. Cyclosporin
        • 5.2.1.2. Oral Corticosteroids
        • 5.2.1.3. Artificial Tears
        • 5.2.1.4. Punctal Plugs
        • 5.2.1.5. Omega Supplement
      • 5.2.2. Global Xerophthalmia Treatment by: Application (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Eye Health Clinics
      • 5.2.3. Global Xerophthalmia Treatment by: Age group (Value)
        • 5.2.3.1. Preschool-Age Children
        • 5.2.3.2. Adolescents
        • 5.2.3.3. Pregnant Women
      • 5.2.4. Global Xerophthalmia Treatment by: Ocular Signs (Value)
        • 5.2.4.1. Night Blindness (XN)
        • 5.2.4.2. Conjunctival Xerosis (X1A)
        • 5.2.4.3. Bitot Spots (X1B)
        • 5.2.4.4. Corneal Xerosis (X2)
        • 5.2.4.5. Corneal Ulceration/Keratomalacia
        • 5.2.4.6. Corneal Ulceration/Keratomalacia
        • 5.2.4.7. Corneal Scar (XS)
        • 5.2.4.8. Xerophthalmic Fundus (XF)
      • 5.2.5. Global Xerophthalmia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Xerophthalmia Treatment (Price)
      • 5.3.1. Global Xerophthalmia Treatment by: Type (Price)
  • 6. Xerophthalmia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Santen Pharmaceutical Co Ltd (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceutical Industries Ltd (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medifit Biologicals (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sentiss (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lupin Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. FDC Limited (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Xerophthalmia Treatment Sale, by Type, Application, Age group, Ocular Signs and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Xerophthalmia Treatment (Value)
      • 7.2.1. Global Xerophthalmia Treatment by: Type (Value)
        • 7.2.1.1. Cyclosporin
        • 7.2.1.2. Oral Corticosteroids
        • 7.2.1.3. Artificial Tears
        • 7.2.1.4. Punctal Plugs
        • 7.2.1.5. Omega Supplement
      • 7.2.2. Global Xerophthalmia Treatment by: Application (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Eye Health Clinics
      • 7.2.3. Global Xerophthalmia Treatment by: Age group (Value)
        • 7.2.3.1. Preschool-Age Children
        • 7.2.3.2. Adolescents
        • 7.2.3.3. Pregnant Women
      • 7.2.4. Global Xerophthalmia Treatment by: Ocular Signs (Value)
        • 7.2.4.1. Night Blindness (XN)
        • 7.2.4.2. Conjunctival Xerosis (X1A)
        • 7.2.4.3. Bitot Spots (X1B)
        • 7.2.4.4. Corneal Xerosis (X2)
        • 7.2.4.5. Corneal Ulceration/Keratomalacia
        • 7.2.4.6. Corneal Ulceration/Keratomalacia
        • 7.2.4.7. Corneal Scar (XS)
        • 7.2.4.8. Xerophthalmic Fundus (XF)
      • 7.2.5. Global Xerophthalmia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Xerophthalmia Treatment (Price)
      • 7.3.1. Global Xerophthalmia Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Xerophthalmia Treatment: by Type(USD Million)
  • Table 2. Xerophthalmia Treatment Cyclosporin , by Region USD Million (2013-2018)
  • Table 3. Xerophthalmia Treatment Oral Corticosteroids , by Region USD Million (2013-2018)
  • Table 4. Xerophthalmia Treatment Artificial Tears , by Region USD Million (2013-2018)
  • Table 5. Xerophthalmia Treatment Punctal Plugs , by Region USD Million (2013-2018)
  • Table 6. Xerophthalmia Treatment Omega Supplement , by Region USD Million (2013-2018)
  • Table 7. Xerophthalmia Treatment: by Application(USD Million)
  • Table 8. Xerophthalmia Treatment Hospital Pharmacies , by Region USD Million (2013-2018)
  • Table 9. Xerophthalmia Treatment Eye Health Clinics , by Region USD Million (2013-2018)
  • Table 10. Xerophthalmia Treatment: by Age group(USD Million)
  • Table 11. Xerophthalmia Treatment Preschool-Age Children , by Region USD Million (2013-2018)
  • Table 12. Xerophthalmia Treatment Adolescents , by Region USD Million (2013-2018)
  • Table 13. Xerophthalmia Treatment Pregnant Women , by Region USD Million (2013-2018)
  • Table 14. Xerophthalmia Treatment: by Ocular Signs(USD Million)
  • Table 15. Xerophthalmia Treatment Night Blindness (XN) , by Region USD Million (2013-2018)
  • Table 16. Xerophthalmia Treatment Conjunctival Xerosis (X1A) , by Region USD Million (2013-2018)
  • Table 17. Xerophthalmia Treatment Bitot Spots (X1B) , by Region USD Million (2013-2018)
  • Table 18. Xerophthalmia Treatment Corneal Xerosis (X2) , by Region USD Million (2013-2018)
  • Table 19. Xerophthalmia Treatment Corneal Ulceration/Keratomalacia , by Region USD Million (2013-2018)
  • Table 20. Xerophthalmia Treatment Corneal Ulceration/Keratomalacia , by Region USD Million (2013-2018)
  • Table 21. Xerophthalmia Treatment Corneal Scar (XS) , by Region USD Million (2013-2018)
  • Table 22. Xerophthalmia Treatment Xerophthalmic Fundus (XF) , by Region USD Million (2013-2018)
  • Table 23. South America Xerophthalmia Treatment, by Country USD Million (2013-2018)
  • Table 24. South America Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 25. South America Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 26. South America Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 27. South America Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 28. Brazil Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 29. Brazil Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 30. Brazil Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 31. Brazil Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 32. Argentina Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 33. Argentina Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 34. Argentina Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 35. Argentina Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 36. Rest of South America Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 37. Rest of South America Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 38. Rest of South America Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 39. Rest of South America Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 40. Asia Pacific Xerophthalmia Treatment, by Country USD Million (2013-2018)
  • Table 41. Asia Pacific Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 42. Asia Pacific Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 43. Asia Pacific Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 44. Asia Pacific Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 45. China Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 46. China Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 47. China Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 48. China Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 49. Japan Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 50. Japan Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 51. Japan Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 52. Japan Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 53. India Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 54. India Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 55. India Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 56. India Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 57. South Korea Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 58. South Korea Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 59. South Korea Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 60. South Korea Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 61. Taiwan Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 62. Taiwan Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 63. Taiwan Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 64. Taiwan Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 65. Australia Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 66. Australia Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 67. Australia Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 68. Australia Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 71. Rest of Asia-Pacific Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 72. Rest of Asia-Pacific Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 73. Europe Xerophthalmia Treatment, by Country USD Million (2013-2018)
  • Table 74. Europe Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 75. Europe Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 76. Europe Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 77. Europe Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 78. Germany Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 79. Germany Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 80. Germany Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 81. Germany Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 82. France Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 83. France Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 84. France Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 85. France Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 86. Italy Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 87. Italy Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 88. Italy Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 89. Italy Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 90. United Kingdom Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 91. United Kingdom Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 92. United Kingdom Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 93. United Kingdom Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 94. Netherlands Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 95. Netherlands Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 96. Netherlands Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 97. Netherlands Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 98. Rest of Europe Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 99. Rest of Europe Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 100. Rest of Europe Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 101. Rest of Europe Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 102. MEA Xerophthalmia Treatment, by Country USD Million (2013-2018)
  • Table 103. MEA Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 104. MEA Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 105. MEA Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 106. MEA Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 107. Middle East Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 108. Middle East Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 109. Middle East Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 110. Middle East Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 111. Africa Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 112. Africa Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 113. Africa Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 114. Africa Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 115. North America Xerophthalmia Treatment, by Country USD Million (2013-2018)
  • Table 116. North America Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 117. North America Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 118. North America Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 119. North America Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 120. United States Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 121. United States Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 122. United States Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 123. United States Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 124. Canada Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 125. Canada Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 126. Canada Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 127. Canada Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 128. Mexico Xerophthalmia Treatment, by Type USD Million (2013-2018)
  • Table 129. Mexico Xerophthalmia Treatment, by Application USD Million (2013-2018)
  • Table 130. Mexico Xerophthalmia Treatment, by Age group USD Million (2013-2018)
  • Table 131. Mexico Xerophthalmia Treatment, by Ocular Signs USD Million (2013-2018)
  • Table 132. Xerophthalmia Treatment: by Type(USD/Units)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Xerophthalmia Treatment: by Type(USD Million)
  • Table 144. Xerophthalmia Treatment Cyclosporin , by Region USD Million (2019-2024)
  • Table 145. Xerophthalmia Treatment Oral Corticosteroids , by Region USD Million (2019-2024)
  • Table 146. Xerophthalmia Treatment Artificial Tears , by Region USD Million (2019-2024)
  • Table 147. Xerophthalmia Treatment Punctal Plugs , by Region USD Million (2019-2024)
  • Table 148. Xerophthalmia Treatment Omega Supplement , by Region USD Million (2019-2024)
  • Table 149. Xerophthalmia Treatment: by Application(USD Million)
  • Table 150. Xerophthalmia Treatment Hospital Pharmacies , by Region USD Million (2019-2024)
  • Table 151. Xerophthalmia Treatment Eye Health Clinics , by Region USD Million (2019-2024)
  • Table 152. Xerophthalmia Treatment: by Age group(USD Million)
  • Table 153. Xerophthalmia Treatment Preschool-Age Children , by Region USD Million (2019-2024)
  • Table 154. Xerophthalmia Treatment Adolescents , by Region USD Million (2019-2024)
  • Table 155. Xerophthalmia Treatment Pregnant Women , by Region USD Million (2019-2024)
  • Table 156. Xerophthalmia Treatment: by Ocular Signs(USD Million)
  • Table 157. Xerophthalmia Treatment Night Blindness (XN) , by Region USD Million (2019-2024)
  • Table 158. Xerophthalmia Treatment Conjunctival Xerosis (X1A) , by Region USD Million (2019-2024)
  • Table 159. Xerophthalmia Treatment Bitot Spots (X1B) , by Region USD Million (2019-2024)
  • Table 160. Xerophthalmia Treatment Corneal Xerosis (X2) , by Region USD Million (2019-2024)
  • Table 161. Xerophthalmia Treatment Corneal Ulceration/Keratomalacia , by Region USD Million (2019-2024)
  • Table 162. Xerophthalmia Treatment Corneal Ulceration/Keratomalacia , by Region USD Million (2019-2024)
  • Table 163. Xerophthalmia Treatment Corneal Scar (XS) , by Region USD Million (2019-2024)
  • Table 164. Xerophthalmia Treatment Xerophthalmic Fundus (XF) , by Region USD Million (2019-2024)
  • Table 165. South America Xerophthalmia Treatment, by Country USD Million (2019-2024)
  • Table 166. South America Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 167. South America Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 168. South America Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 169. South America Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 170. Brazil Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 171. Brazil Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 172. Brazil Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 173. Brazil Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 174. Argentina Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 175. Argentina Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 176. Argentina Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 177. Argentina Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 178. Rest of South America Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 179. Rest of South America Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 180. Rest of South America Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 181. Rest of South America Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 182. Asia Pacific Xerophthalmia Treatment, by Country USD Million (2019-2024)
  • Table 183. Asia Pacific Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 184. Asia Pacific Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 185. Asia Pacific Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 186. Asia Pacific Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 187. China Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 188. China Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 189. China Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 190. China Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 191. Japan Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 192. Japan Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 193. Japan Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 194. Japan Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 195. India Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 196. India Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 197. India Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 198. India Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 199. South Korea Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 200. South Korea Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 201. South Korea Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 202. South Korea Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 203. Taiwan Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 204. Taiwan Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 205. Taiwan Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 206. Taiwan Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 207. Australia Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 208. Australia Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 209. Australia Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 210. Australia Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 211. Rest of Asia-Pacific Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 212. Rest of Asia-Pacific Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 213. Rest of Asia-Pacific Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 214. Rest of Asia-Pacific Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 215. Europe Xerophthalmia Treatment, by Country USD Million (2019-2024)
  • Table 216. Europe Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 217. Europe Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 218. Europe Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 219. Europe Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 220. Germany Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 221. Germany Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 222. Germany Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 223. Germany Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 224. France Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 225. France Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 226. France Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 227. France Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 228. Italy Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 229. Italy Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 230. Italy Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 231. Italy Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 232. United Kingdom Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 233. United Kingdom Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 234. United Kingdom Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 235. United Kingdom Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 236. Netherlands Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 237. Netherlands Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 238. Netherlands Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 239. Netherlands Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 240. Rest of Europe Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 241. Rest of Europe Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 242. Rest of Europe Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 243. Rest of Europe Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 244. MEA Xerophthalmia Treatment, by Country USD Million (2019-2024)
  • Table 245. MEA Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 246. MEA Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 247. MEA Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 248. MEA Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 249. Middle East Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 250. Middle East Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 251. Middle East Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 252. Middle East Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 253. Africa Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 254. Africa Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 255. Africa Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 256. Africa Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 257. North America Xerophthalmia Treatment, by Country USD Million (2019-2024)
  • Table 258. North America Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 259. North America Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 260. North America Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 261. North America Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 262. United States Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 263. United States Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 264. United States Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 265. United States Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 266. Canada Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 267. Canada Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 268. Canada Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 269. Canada Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 270. Mexico Xerophthalmia Treatment, by Type USD Million (2019-2024)
  • Table 271. Mexico Xerophthalmia Treatment, by Application USD Million (2019-2024)
  • Table 272. Mexico Xerophthalmia Treatment, by Age group USD Million (2019-2024)
  • Table 273. Mexico Xerophthalmia Treatment, by Ocular Signs USD Million (2019-2024)
  • Table 274. Xerophthalmia Treatment: by Type(USD/Units)
  • Table 275. Research Programs/Design for This Report
  • Table 276. Key Data Information from Secondary Sources
  • Table 277. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Xerophthalmia Treatment: by Type USD Million (2013-2018)
  • Figure 5. Global Xerophthalmia Treatment: by Application USD Million (2013-2018)
  • Figure 6. Global Xerophthalmia Treatment: by Age group USD Million (2013-2018)
  • Figure 7. Global Xerophthalmia Treatment: by Ocular Signs USD Million (2013-2018)
  • Figure 8. South America Xerophthalmia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Xerophthalmia Treatment Share (%), by Country
  • Figure 10. Europe Xerophthalmia Treatment Share (%), by Country
  • Figure 11. MEA Xerophthalmia Treatment Share (%), by Country
  • Figure 12. North America Xerophthalmia Treatment Share (%), by Country
  • Figure 13. Global Xerophthalmia Treatment: by Type USD/Units (2013-2018)
  • Figure 14. Global Xerophthalmia Treatment share by Players 2018 (%)
  • Figure 15. Global Xerophthalmia Treatment share by Players (Top 3) 2018(%)
  • Figure 16. Global Xerophthalmia Treatment share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 20. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2018
  • Figure 22. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 24. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2018
  • Figure 26. Santen Pharmaceutical Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Santen Pharmaceutical Co Ltd (Japan) Revenue: by Geography 2018
  • Figure 28. Sun Pharmaceutical Industries Ltd (India) Revenue, Net Income and Gross profit
  • Figure 29. Sun Pharmaceutical Industries Ltd (India) Revenue: by Geography 2018
  • Figure 30. Medifit Biologicals (India) Revenue, Net Income and Gross profit
  • Figure 31. Medifit Biologicals (India) Revenue: by Geography 2018
  • Figure 32. Sentiss (India) Revenue, Net Income and Gross profit
  • Figure 33. Sentiss (India) Revenue: by Geography 2018
  • Figure 34. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Lupin Limited (India) Revenue: by Geography 2018
  • Figure 36. FDC Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. FDC Limited (India) Revenue: by Geography 2018
  • Figure 38. Global Xerophthalmia Treatment: by Type USD Million (2019-2024)
  • Figure 39. Global Xerophthalmia Treatment: by Application USD Million (2019-2024)
  • Figure 40. Global Xerophthalmia Treatment: by Age group USD Million (2019-2024)
  • Figure 41. Global Xerophthalmia Treatment: by Ocular Signs USD Million (2019-2024)
  • Figure 42. South America Xerophthalmia Treatment Share (%), by Country
  • Figure 43. Asia Pacific Xerophthalmia Treatment Share (%), by Country
  • Figure 44. Europe Xerophthalmia Treatment Share (%), by Country
  • Figure 45. MEA Xerophthalmia Treatment Share (%), by Country
  • Figure 46. North America Xerophthalmia Treatment Share (%), by Country
  • Figure 47. Global Xerophthalmia Treatment: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Novartis AG (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Santen Pharmaceutical Co Ltd (Japan)
  • Sun Pharmaceutical Industries Ltd (India)
  • Medifit Biologicals (India)
  • Sentiss (India)
  • Lupin Limited (India)
  • FDC Limited (India)
Select User Access Type

Key Highlights of Report


Jul 2019 230 Pages 80 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Xerophthalmia Treatment Quantitative research analysis
Global Xerophthalmia Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Xerophthalmia Treatment Report?

Have a Query? Click Here

Other Related Reports

Tularaemia Treatment Comprehensive Study by Application (Hospital, Clinic, Others), Disease Type (Ulceroglandular, Glandular, Oculoglandular, Oropharyngeal, Intestinal, Pneumonic, Typhoidal), Drugs T...
$ 3450
Antiarrhythmic Drugs Comprehensive Study by Type (Oral Antiarrhythmic, Intravenous Antiarryhthmic), Application (Hospitals, Cardiac Centers, Ambulatory Surgical Centers), Distribution Channel (Direct...
$ 3350
Oligonucleotide Synthesis Comprehensive Study by Type (Oligonucleotide-Based Drugs, Synthesized Oligonucleotides, Reagents, Others), Application (Therapeutic, Research, Diagnostic), End-User (Hospita...
$ 3800
Bronchitis Drug Comprehensive Study by Type (Bronchodilators, Cough Suppressants and Expectorants, Anti-allergic, Nonsteroidal Anti-inflammatories (NSAIDs), Corticosteroids), Application (Hospitals, ...
$ 3450
Osteomyelitis Treatment Comprehensive Study by Type (CG-400549, Dalbavancin, MTF-101, VCD-008, Others), Application (Clinic, Hospital, Others) Players and Region - Global Market Outlook to 2027
$ 3500
Chronic Kidney Disease Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug class (ACE Inhibitors, Angiotensin-II receptor blockers, Calcium c...
$ 3450